3-6--dithiothalidomide has been researched along with Encephalitis* in 2 studies
2 other study(ies) available for 3-6--dithiothalidomide and Encephalitis
Article | Year |
---|---|
3,6'-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation.
Tumor necrosis factor-α (TNF) plays a prominent role in the brain damage and functional deficits that result from ischemic stroke. It was recently reported that the thalidomide analog 3,6'-dithiothalidomide (3,6'-DT) can selectively inhibit the synthesis of TNF in cultured cells. We therefore tested the therapeutic potential of 3,6'-DT in a mouse model of focal ischemic stroke. Administration of 3,6'-DT immediately prior to a stroke or within 3 hr after the stroke reduced infarct volume, neuronal death, and neurological deficits, whereas thalidomide was effective only when administered prior to stroke. Neuroprotection was accompanied by decreased inflammation; 3,6'-DT-treated mice exhibited reduced expression of TNF, interleukin-1β, and inducible nitric oxide synthase; reduced numbers of activated microglia/macrophages, astrocytes, and neutrophils; and reduced expression of intercellular adhesion molecule-1 in the ischemic brain tissue. 3,6'-DT treatment attenuated stroke-induced disruption of the blood-brain barrier by a mechanism that appears to involve suppression of matrix metalloproteinase-9 and preservation of occludin. Treatment with 3,6'-DT did not reduce ischemic brain damage in mice lacking TNF receptors, consistent with a critical role for suppression of TNF production and TNF signaling in the therapeutic action of 3,6'-DT. These findings suggest that anti-inflammatory mechanisms underlie the therapeutic actions of 3,6-DT in an animal model of stroke. Topics: Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Brain Infarction; Cell Death; Cytokines; Disease Models, Animal; Encephalitis; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Granulocyte Colony-Stimulating Factor; In Situ Nick-End Labeling; Intercellular Adhesion Molecule-1; Interleukin-3; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neutrophil Infiltration; Neutrophils; Nitric Oxide Synthase Type II; Recombinant Fusion Proteins; Stroke; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |
TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation.
Chronic neuroinflammation is a hallmark of several neurological disorders associated with cognitive loss. Activated microglia and secreted factors such as tumor necrosis factor (TNF)-α are key mediators of neuroinflammation and may contribute to neuronal dysfunction. Our study was aimed to evaluate the therapeutic potential of a novel analog of thalidomide, 3,6'-dithiothalidomide (DT), an agent with anti-TNF-α activity, in a model of chronic neuroinflammation.. Lipopolysaccharide or artificial cerebrospinal fluid was infused into the fourth ventricle of three-month-old rats for 28 days. Starting on day 29, animals received daily intraperitoneal injections of DT (56 mg/kg/day) or vehicle for 14 days. Thereafter, cognitive function was assessed by novel object recognition, novel place recognition and Morris water maze, and animals were euthanized 25 min following water maze probe test evaluation.. Chronic LPS-infusion was characterized by increased gene expression of the proinflammatory cytokines TNF-α and IL-1β in the hippocampus. Treatment with DT normalized TNF-α levels back to control levels but not IL-1β. Treatment with DT attenuated the expression of TLR2, TLR4, IRAK1 and Hmgb1, all genes involved in the TLR-mediated signaling pathway associated with classical microglia activation. However DT did not impact the numbers of MHC Class II immunoreactive cells. Chronic neuroinflammation impaired novel place recognition, spatial learning and memory function; but it did not impact novel object recognition. Importantly, treatment with DT restored cognitive function in LPS-infused animals and normalized the fraction of hippocampal neurons expressing the plasticity-related immediate-early gene Arc.. Our data demonstrate that the TNF-α synthesis inhibitor DT can significantly reverse hippocampus-dependent cognitive deficits induced by chronic neuroinflammation. These results suggest that TNF-α is a critical mediator of chronic neuroinflammation-induced neuronal dysfunction and cognitive impairment and targeting its synthesis could provide an effective therapeutic approach to several human neurodegenerative diseases. Topics: Analysis of Variance; Animals; Apoptosis Regulatory Proteins; Cognition Disorders; Disease Models, Animal; Encephalitis; Enzyme Inhibitors; Exploratory Behavior; Gene Expression Regulation, Enzymologic; Hippocampus; Histocompatibility Antigens Class II; Male; Maze Learning; Neuropsychological Tests; Polysaccharides; Rats; Rats, Inbred F344; Recognition, Psychology; Signal Transduction; Space Perception; Thalidomide; Time Factors; Tumor Necrosis Factor-alpha | 2012 |